[1]
Northrup H,Aronow ME,Bebin EM,Bissler J,Darling TN,de Vries PJ,Frost MD,Fuchs Z,Gosnell ES,Gupta N,Jansen AC,Jóźwiak S,Kingswood JC,Knilans TK,McCormack FX,Pounders A,Roberds SL,Rodriguez-Buritica DF,Roth J,Sampson JR,Sparagana S,Thiele EA,Weiner HL,Wheless JW,Towbin AJ,Krueger DA,International Tuberous Sclerosis Complex Consensus Group., Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric neurology. 2021 Oct;
[PubMed PMID: 34399110]
Level 3 (low-level) evidence
[2]
Shaw BM,Kopras E,Gupta N, Menstrual Cycle-related Respiratory Symptom Variability in Patients with Lymphangioleiomyomatosis. Annals of the American Thoracic Society. 2022 Sep
[PubMed PMID: 35649208]
[3]
Huang J,Xu W,Liu P,Liu Y,Shen C,Liu S,Wang Y,Wang J,Zhang T,He Y,Cheng C,Yang L,Zhang W,Tian X,Xu KF, Gene mutations in sporadic lymphangioleiomyomatosis and genotype-phenotype correlation analysis. BMC pulmonary medicine. 2022 Sep 18;
[PubMed PMID: 36117164]
[4]
Wakida K,Watanabe Y,Kumasaka T,Seyama K,Mitani K,Hiraki T,Kamimura G,Nagata T,Nakamura Y,Sato M, Lymphangioleiomyomatosis in a Male. The Annals of thoracic surgery. 2015 Sep
[PubMed PMID: 26354644]
[5]
McCarthy C,Gupta N,Johnson SR,Yu JJ,McCormack FX, Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. The Lancet. Respiratory medicine. 2021 Nov
[PubMed PMID: 34461049]
[6]
Muzykewicz DA,Sharma A,Muse V,Numis AL,Rajagopal J,Thiele EA, TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. Journal of medical genetics. 2009 Jul
[PubMed PMID: 19419980]
[7]
Curatolo P,Specchio N,Aronica E, Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. The Lancet. Neurology. 2022 Sep;
[PubMed PMID: 35963265]
Level 3 (low-level) evidence
[8]
Tyburczy ME,Dies KA,Glass J,Camposano S,Chekaluk Y,Thorner AR,Lin L,Krueger D,Franz DN,Thiele EA,Sahin M,Kwiatkowski DJ, Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS genetics. 2015 Nov;
[PubMed PMID: 26540169]
[9]
Harknett EC, Chang WY, Byrnes S, Johnson J, Lazor R, Cohen MM, Gray B, Geiling S, Telford H, Tattersfield AE, Hubbard RB, Johnson SR. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM : monthly journal of the Association of Physicians. 2011 Nov:104(11):971-9. doi: 10.1093/qjmed/hcr116. Epub 2011 Jul 15
[PubMed PMID: 21764810]
[10]
Johnson SR,Cordier JF,Lazor R,Cottin V,Costabel U,Harari S,Reynaud-Gaubert M,Boehler A,Brauner M,Popper H,Bonetti F,Kingswood C,Review Panel of the ERS LAM Task Force., European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. The European respiratory journal. 2010 Jan;
[PubMed PMID: 20044458]
[11]
Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL, NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. American journal of respiratory and critical care medicine. 2006 Jan 1:173(1):105-11
[PubMed PMID: 16210669]
[13]
Cudzilo CJ,Szczesniak RD,Brody AS,Rattan MS,Krueger DA,Bissler JJ,Franz DN,McCormack FX,Young LR, Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 2013 Aug;
[PubMed PMID: 23539171]
[14]
Kristof AS,Zhi Li P,Major P,Landry JS, Lymphangioleiomyomatosis and Tuberous Sclerosis Complex in Quebec: Prevalence and Health-care Utilization. Chest. 2015 Aug
[PubMed PMID: 25789699]
[15]
Carel H, Breathlessness: the rift between objective measurement and subjective experience. The Lancet. Respiratory medicine. 2018 May
[PubMed PMID: 29523434]
[16]
Tobino K,Johkoh T,Fujimoto K,Sakai F,Arakawa H,Kurihara M,Kumasaka T,Koike K,Takahashi K,Seyama K, Computed tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients. European journal of radiology. 2015 Mar
[PubMed PMID: 25544557]
[17]
Wei CC,Hsiao YP,Gau SY,Wu YT,Wu CT,Wu MH,Tsai JD, The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma. Dermatology (Basel, Switzerland). 2021
[PubMed PMID: 33032292]
[18]
Kingswood JC,Belousova E,Benedik MP,Carter T,Cottin V,Curatolo P,Dahlin M,D'Amato L,Beaure d'Augères G,de Vries PJ,Ferreira JC,Feucht M,Fladrowski C,Hertzberg C,Jozwiak S,Lawson JA,Macaya A,Marques R,Nabbout R,O'Callaghan F,Qin J,Sander V,Shah S,Takahashi Y,Touraine R,Youroukos S,Zonnenberg B,Jansen AC,Sauter M, Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Frontiers in neurology. 2020;
[PubMed PMID: 33041968]
Level 2 (mid-level) evidence
[19]
Chang WY,Cane JL,Blakey JD,Kumaran M,Pointon KS,Johnson SR, Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respiratory research. 2012 Apr 18
[PubMed PMID: 22513045]
[20]
Hagaman JT,Schauer DP,McCormack FX,Kinder BW, Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. American journal of respiratory and critical care medicine. 2010 Jun 15
[PubMed PMID: 20167846]
[21]
Gupta N,Finlay GA,Kotloff RM,Strange C,Wilson KC,Young LR,Taveira-DaSilva AM,Johnson SR,Cottin V,Sahn SA,Ryu JH,Seyama K,Inoue Y,Downey GP,Han MK,Colby TV,Wikenheiser-Brokamp KA,Meyer CA,Smith K,Moss J,McCormack FX,ATS Assembly on Clinical Problems., Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. American journal of respiratory and critical care medicine. 2017 Nov 15;
[PubMed PMID: 29140122]
Level 1 (high-level) evidence
[22]
Blute ML, How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? American journal of respiratory and critical care medicine. 1996 Nov;
[PubMed PMID: 8912787]
[23]
Engels K,Stauber R,Magnussen H,Kirsten D,Watz H,Wirtz H, Angiomyolipomas are indicator lesions for sporadic lymphangioleiomyomatosis in women. European urology. 2009 Mar;
[PubMed PMID: 18835088]
[24]
Rivera G,Gokaslan T,Kurian EM, Lymphangioleiomyomatosis diagnosed by effusion cytology: A case report. Journal of cytology. 2015 Oct-Dec
[PubMed PMID: 26811583]
Level 3 (low-level) evidence
[25]
McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J, ATS/JRS Committee on Lymphangioleiomyomatosis. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. American journal of respiratory and critical care medicine. 2016 Sep 15:194(6):748-61. doi: 10.1164/rccm.201607-1384ST. Epub
[PubMed PMID: 27628078]
Level 1 (high-level) evidence
[26]
Young LR,Vandyke R,Gulleman PM,Inoue Y,Brown KK,Schmidt LS,Linehan WM,Hajjar F,Kinder BW,Trapnell BC,Bissler JJ,Franz DN,McCormack FX, Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010 Sep
[PubMed PMID: 20382711]
[27]
Taveira-DaSilva AM,Steagall WK,Rabel A,Hathaway O,Harari S,Cassandro R,Stylianou M,Moss J, Reversible airflow obstruction in lymphangioleiomyomatosis. Chest. 2009 Dec
[PubMed PMID: 19447921]
[28]
Araujo MS,Baldi BG,Freitas CS,Albuquerque AL,Marques da Silva CC,Kairalla RA,Carvalho CR,Carvalho CR, Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial. The European respiratory journal. 2016 May
[PubMed PMID: 26917604]
Level 1 (high-level) evidence
[29]
McCormack FX,Inoue Y,Moss J,Singer LG,Strange C,Nakata K,Barker AF,Chapman JT,Brantly ML,Stocks JM,Brown KK,Lynch JP 3rd,Goldberg HJ,Young LR,Kinder BW,Downey GP,Sullivan EJ,Colby TV,McKay RT,Cohen MM,Korbee L,Taveira-DaSilva AM,Lee HS,Krischer JP,Trapnell BC, Efficacy and safety of sirolimus in lymphangioleiomyomatosis. The New England journal of medicine. 2011 Apr 28
[PubMed PMID: 21410393]
[30]
Neurohr C,Hoffmann AL,Huppmann P,Herrera VA,Ihle F,Leuschner S,von Wulffen W,Meis T,Baezner C,Leuchte H,Baumgartner R,Zimmermann G,Behr J, Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? Respiratory research. 2011 May 21
[PubMed PMID: 21600034]
[31]
Gupta N,Lee HS,Young LR,Strange C,Moss J,Singer LG,Nakata K,Barker AF,Chapman JT,Brantly ML,Stocks JM,Brown KK,Lynch JP 3rd,Goldberg HJ,Downey GP,Taveira-DaSilva AM,Krischer JP,Setchell K,Trapnell BC,Inoue Y,McCormack FX,NIH Rare Lung Disease Consortium., Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. The European respiratory journal. 2019 Apr;
[PubMed PMID: 30846465]
[32]
Wang Q,Luo M,Xiang B,Chen S,Ji Y, The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. Respiratory research. 2020 Feb 14;
[PubMed PMID: 32059669]
[33]
Bissler JJ,Nonomura N,Budde K,Zonnenberg BA,Fischereder M,Voi M,Louveau AL,Herbst F,Bebin EM,Curatolo P,Zonta A,Belousova E, Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PloS one. 2018
[PubMed PMID: 30192751]
[34]
Budde K,Zonnenberg BA,Frost M,Cheung W,Urva S,Brechenmacher T,Stein K,Chen D,Kingswood JC,Bissler JJ, Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. British journal of clinical pharmacology. 2016 May
[PubMed PMID: 26580489]
[35]
Oprescu N,McCormack FX,Byrnes S,Kinder BW, Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung. 2013 Feb
[PubMed PMID: 23007140]
[36]
Almoosa KF,Ryu JH,Mendez J,Huggins JT,Young LR,Sullivan EJ,Maurer J,McCormack FX,Sahn SA, Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest. 2006 May;
[PubMed PMID: 16685019]
[37]
Gupta N,Johnson SR,Moss J,McCormack FX, Reply to Yanagisawa: Treatment of Pulmonary Lymphangioleiomyomatosis during Pregnancy. American journal of respiratory and critical care medicine. 2018 Jun 1
[PubMed PMID: 29356560]